Chairman of the Executive Board/CEO
Since Sep. 1st 2018, Peter Goldschmidt is CEO of STADA Arzneimittel AG. He strongly pursuits the STADA vision, to be the partner of choice in generics, specialty medicines and consumer health in Europe and selected emerging markets, while continuously outgrowing the industry in terms of growth and profitability.
Peter Goldschmidt has 30 years’ experience and success in the pharmaceutical industry. He worked in OTC, Generics and the innovative Pharma Business in Asia, Europe and the US in several different leadership functions. From 2013 through 2018, Peter Goldschmidt was President of Sandoz US and Head of North America. He served on the Board of Directors as Vice Chair of Association for Accessible Medicines (AAM), the generics and biosimilar industry association in the U.S. Prior to this, he was Head of Sandoz Central and Eastern Europe and member of the Global Sandoz Executive Committee.
Over the past three years at STADA, Peter Goldschmidt has led the group on a cultural journey, implementing a growth mindset culture based around the common purpose of “Caring for People’s Health as a Trusted Partner”. By ensuring that all of STADA’s almost 13,000 employees worldwide truly live the four STADA values of Agility, Entrepreneurship, Integrity and One STADA, he has led the group in consistently delivering above-market sales and profit growth. As a top-five supplier of both generic and consumer healthcare products in Europe, STADA helps millions of people to lead healthy, dignified and fulfilled lives.
A German national, he is a graduate in politics and economic geography – and hold a master’s degree in sociology – from the University of Muenster in Germany. He has completed post-graduate studies at the London Business School, UK, and at the Harvard Business School and Stanford Business School in the US.